TW202400230A - 乳癌的組合療法 - Google Patents

乳癌的組合療法 Download PDF

Info

Publication number
TW202400230A
TW202400230A TW112109034A TW112109034A TW202400230A TW 202400230 A TW202400230 A TW 202400230A TW 112109034 A TW112109034 A TW 112109034A TW 112109034 A TW112109034 A TW 112109034A TW 202400230 A TW202400230 A TW 202400230A
Authority
TW
Taiwan
Prior art keywords
fdc
breast cancer
dose
trastuzumab
combination
Prior art date
Application number
TW112109034A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼爾 艾格
馬克 安東尼 哈夫納
莎拉 路易斯 韓森
席亞拉 梅特卡夫
米納 尼康將
拉夫 波普
艾雷諾拉 雷斯圖西亞
馬赫什 拉坦拉爾 希夫哈爾
靜 朱
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202400230A publication Critical patent/TW202400230A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW112109034A 2022-03-14 2023-03-10 乳癌的組合療法 TW202400230A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269326P 2022-03-14 2022-03-14
US63/269,326 2022-03-14

Publications (1)

Publication Number Publication Date
TW202400230A true TW202400230A (zh) 2024-01-01

Family

ID=85937455

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112109034A TW202400230A (zh) 2022-03-14 2023-03-10 乳癌的組合療法

Country Status (11)

Country Link
US (1) US20250177364A1 (https=)
EP (1) EP4493180A1 (https=)
JP (1) JP2025509510A (https=)
KR (1) KR20240163084A (https=)
CN (1) CN118843461A (https=)
AU (1) AU2023234511A1 (https=)
CA (1) CA3254271A1 (https=)
IL (1) IL315153A (https=)
MX (1) MX2024011183A (https=)
TW (1) TW202400230A (https=)
WO (1) WO2023178019A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2437300A (en) 1999-01-15 2000-08-01 Infineum International Ltd Improved fuel compositions
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
TWI800827B (zh) * 2020-05-12 2023-05-01 美商建南德克公司 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
MX2023000622A (es) 2020-07-14 2023-02-22 Genentech Inc Ensayos para combinaciones de dosis fija.

Also Published As

Publication number Publication date
JP2025509510A (ja) 2025-04-11
KR20240163084A (ko) 2024-11-18
EP4493180A1 (en) 2025-01-22
AU2023234511A1 (en) 2024-09-12
IL315153A (en) 2024-10-01
CN118843461A (zh) 2024-10-25
CA3254271A1 (en) 2023-09-21
US20250177364A1 (en) 2025-06-05
MX2024011183A (es) 2024-09-18
WO2023178019A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20250177364A1 (en) Combination therapies for breast cancer
KR100695383B1 (ko) 암을 치료하기 위한 도세탁셀과 ｒｈｕＭＡｂ ＨＥＲ２의조합제제
US8895001B2 (en) Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
AU2013243584A1 (en) Dosage and administration of monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
Loew et al. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms
CN103562226A (zh) 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CN108697801A (zh) 使用liv1-adc和化学治疗的组合疗法
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
KR20150030199A (ko) 항암 치료제와 병용하는 이중특이적 scfv 콘쥬게이트의 용량 및 투여
US20210040224A1 (en) Cd47 blockade therapy with cd38 antibody
JP2017515843A (ja) 抗ｅｇｆｒ治療薬の投与量および投与
AU2019235627B2 (en) Improvements in CD47 blockade therapy by EGFR antibody
US20210113692A1 (en) Dosing regimen
C. Quant et al. Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma